RE:RE:RE:RE:Annual meeting Many have said it before the valuation is the projection of the market's perception so the market didn't ascribe any value to phase 3 NASH even with FDA's go a head meaning market doesn't believe in their program at all despite the fact that the agency does.
Now we know their approach is different which is the possible reason why the market doesn't understand it, they managed to convince the agency now they have to convince the market and that's where it all falls apart. The market equaled difference as no value so the company has to change that perception...
Bucknelly21 wrote: I'm curious does getting the fda letter to proceed for phase 3 and the market not even sniffing at it the same kind of irrational market behavior you are referring too?